Boston Scientific Corporation (LON:0HOY)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 115.73B |
| Revenue (ttm) | 13.50B |
| Net Income (ttm) | 1.83B |
| Shares Out | n/a |
| EPS (ttm) | 1.23 |
| PE Ratio | 63.29 |
| Forward PE | 33.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,232 |
| Average Volume | 3,154 |
| Open | 106.05 |
| Previous Close | 106.31 |
| Day's Range | 104.87 - 106.09 |
| 52-Week Range | 78.60 - 109.09 |
| Beta | 0.66 |
| RSI | 53.09 |
| Earnings Date | Oct 22, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
IBD Stock Of The Day Boston Scientific Breaks Out — Here's Why
Boston Scientific is Wednesday's IBD Stock Of The Day. Shares are breaking a short-term trendline at their 50-day moving average.
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Boston Scientific (NYSE: BSX) has outperformed the market over the past 10 years by 7.53% on an annualized basis producing an average annual return of 20.65%. Currently, Boston Scientific has a marke...
Boston Scientific Stock Hits A Record High, Consolidates. Prepping For Another Run?
Boston Scientific shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific’s AI leadership, global growth, and strong R&D make it a long-term winner despite valuation and regulatory risks. See why BSX stock is a buy.
Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue
The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE: BSX) ENDOTAK RELIANCE defibrillation leads, followi...
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.
10 stocks favored to gain up to 30% in a sector that has missed this year's rally
All but two of the S&P 500's sectors are up so far in 2025.
What's Driving the Market Sentiment Around Boston Scientific?
Boston Scientific's (NYSE: BSX) short percent of float has risen 3.1% since its last report. The company recently reported that it has 19.57 million shares sold short , which is 1.33% of all regular ...
This health care stock forming a 'big base breakout' is ready to separate from the pack, charts indicate
David Keller breaks down the charts in Boston Scientific.
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Cramer's Stop Trading: Boston Scientific
Jim Cramer breaks down why he's keeping an eye on shares of Boston Scientific.
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Stronger‑than‑expected sales and raised full‑year guidance underscore Boston Scientific Corporation ‘s (NYSE: BSX) momentum—and hint at where its next product wins may come. Boston Scientific on Wedn...
Cramer's Stop Trading: Boston Scientific
Jim Cramer breaks down why he's keeping an eye on shares of Boston Scientific.
Boston Scientific Eyes Breakout On Strong Second Quarter, Guidance
Boston Scientific stock jumped early Wednesday on a strong second-quarter report and guidance for the full year.
Boston Scientific lifts annual profit view on steady heart devices demand
Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates.
Boston Scientific Non-GAAP EPS of $0.75 beats by $0.02, revenue of $5.06B beats by $170M
Boston Scientific announces results for second quarter 2025
MARLBOROUGH, Mass. , July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported...
Earnings Scheduled For July 23, 2025
Companies Reporting Before The Bell • Equinor (NYSE: EQNR) is projected to report quarterly earnings at $0.26 per share on revenue of $24.67 billion. • Thermo Fisher Scientific (NYSE: TMO) is expect...
Boston Scientific Q2 2025 Earnings Preview
How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings?
Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% o...
Boston Scientific Stock Is on Pause. Its Earnings Could Get It Moving Higher Again.
North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key Companies - Boston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf
Explore the "North America Ureteroscopes Market Outlook to 2033" for key insights into the Ureteroscopes market. The report covers annualized market revenues, volume, and average prices across segment...
Boston Scientific gets FDA nod for expanded labeling of Farapulse
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH, Mass. , July 7, 2025 /PRNewswire/ -- Boston Scientific...